age1 β Full Portfolio
26 tracked investments Β· listed companies and verified rows first
ALX Oncology is a clinical-stage biopharmaceutical company developing cancer therapies, including its lead candidate evorpacept for immuno-oncology and ALX2004, an antibody-drug conjugate targeting EGFR-positive tumors.
BiotechHealthtech
Co-investorsForesite CapitalLightstone VenturesvenBio Partners
Intellia Therapeutics develops in vivo and ex vivo CRISPR/Cas9 gene editing therapies aimed at treating the root causes of severe genetic diseases, with lead candidates for hereditary angioedema and ATTR amyloidosis.
BiotechDeep TechHealthtechCambridge, US
Nessan Bermingham(Executive Officer, Director)Jennifer Doudna(Co-founder)Jose Rivera(Executive Officer)John Leonard(President and Chief Executive Officer)James Basta(Executive Vice President, General Counsel and Corporate Secretary)Edward Dulac(Executive Vice President, Chief Financial Officer)
Co-investorsAtlas VentureAvoro Capital AdvisorsEcoR1 CapitalForesite Capital
Precision BioSciences develops gene-editing medicines using its proprietary ARCUS genome editing platform, which employs sequence-specific nuclease enzymes to insert, remove, or repair DNA in living cells to treat hard-to-treat conditions including rare genetic diseases and hepatitis B (HBV).
BiotechDeep TechHealthtechDurham, US
JEFF SMITH(Executive Officer)DEREK JANTZ(Executive Officer, Director)MATTHEW KANE(Executive Officer, Director)Jeff Smith(Co-founder)Derek Jantz(Co-founder)TODD MELBY(Executive Officer)
Co-investorsAliment CapitalBrace PharmaF-Prime CapitalOCV PartnersOUP (Osage University Partners)Pontifax AgTech+4 more
Autonomy Bio is a biotech company developing drugs targeting human aging to extend healthy lifespan.
BiotechLongevitySan Francisco, US
Co-investorsValhalla VenturesKleiner PerkinsSoftBank Group
Aerska develops RNA interference (RNAi) medicines designed for targeted delivery across the blood-brain barrier to treat, delay, and prevent central nervous system and neurological diseases.
BiotechDeep TechHealthtechMedical Devices
Stuart Milstein(Co-Founder)Jack OβMearaJack O'Meara(Cofounder)in
Co-investorsBlueYard CapitalEntrepreneur FirstIaso VenturesPsyMed VenturesUnruly CapitalAda Ventures
Aperture Therapeutics uses machine learning to mine genomic and clinical datasets for naturally occurring protective gene variants, then designs oligonucleotide therapeutics that mimic those variants to treat neurodegenerative diseases such as ALS and FTD and delay brain aging.
AI & Machine LearningBiotechLongevity
Martin Jacko(Founder & CEO)
Arda develops therapeutics using single-cell computational biology to target and eliminate pathogenic cells in chronic diseases.
AI & Machine LearningBiotechMedical DevicesAustin, US
Adam Freund(Founder & Chief Executive Officer)Remi-Martin Laberge(Founder and Chief Technology Officer)
BoardVineeta Agarwala(Director)in
Co-investorsAndreessen HorowitzStrawberry Creek VenturesAlumni VenturesGaingelsGV (Google Ventures)Indicator Ventures+3 more
Conception develops stem cell technology to create functional reproductive cells in the laboratory, enabling in-vitro gametogenesis as a solution for individuals facing biological and medical fertility barriers.
BiotechDeep TechHealthtech
Matt Krisiloff(CEO)inBianka Seres(President)
Co-investorsCompoundHOF CapitalMetaplanetSciFoundersVU Venture Partners
Originator of Otarmeni (lunsotogene parvec-cwha), an FDA-approved gene therapy for genetic hearing loss; acquired by Regeneron in 2023.
Cambridge, US
Co-investorsSamsara BioCapitalThird Rock Ventures
Deciduous Therapeutics develops small molecule and immunomodulatory therapies targeting senescent cells to treat age-related diseases including Type 1 diabetes, autoimmunity, and metabolic disorders.
BiotechDigital HealthLongevitySan Francisco, US
Robin Mansukhani(CEO and Co-Founder)inAnil Bhushan(Scientific Founder)in
BoardDylan Morris(Director)in
Co-investorsBold Capital PartnersCornucopian Capital ManagementCRV (Charles River Ventures)Owl CapitalquadraScope Venture FundAxial VC+1 more
Fauna Bio applies AI and computational analysis to its proprietary biobank of data from extreme mammals such as hibernating species to identify drug targets that are conserved across species including humans.
AI & Machine LearningBiotechDeep TechHealthtechEmeryville, US
Linda Goodman(Founder)inAshley(CEO)
Co-investorsFarvatn VentureGRIDS CapitalLifeforce CapitalMetaplanetVibe CapitalBeagle Ventures+3 more
General Control is developing programmable, multiplexed epigenetic editing therapies designed to control the expression of several genes at once.
BiotechDeep TechLongevity
Lada Nuzhna(CEO & Founder)
Co-investorsAngel Collective Opportunity FundGoAhead VenturesMoth FundStreamlined Ventures
General Proximity develops proximity-based technologies for drug discovery and development.
AI & Machine LearningBiotechDeep TechHealthtechSan Francisco, US
Armand Cognetta(Founder)in
Co-investorsY CombinatorFelicis VenturesModi Ventures
Gordian Biotechnology develops therapies aimed at treating age-related diseases to extend healthy lifespan.
AI & Machine LearningBiotechHealthtechLongevity
Co-investorsFifty YearsMetaplanetPrime Movers LabStreamlined VenturesW ventures10x Founders
The Longevity Fund is a venture capital firm founded in 2011 to back founder-led biotech companies developing drugs for longevity and age-related diseases.
BiotechLongevity
Laura Deming(Founder)Alex Colville(General Partner)
Co-investors1517
Loyal develops therapeutics to help dogs live longer and healthier lives, focusing on canine aging research and longevity interventions for companion dogs.
BiotechHealthtechLongevity
Celine Halioua(Founder & CEO)in
Co-investorsCollaborative FundFirst Round CapitalFlucas VenturesKhosla VenturesMetaplanetShrug Capital+4 more
Therapies for gastrointestinal and liver disease (NASDAQ: MTCR).
San Diego clinical-stage biopharma developing non-bile acid FXR agonists for liver and gastrointestinal diseases.
BiotechSan Diego, US
Ronald Evans(Director)Trisha Millican(Executive Officer)Ken Song(Executive Officer, Director)
BoardKristina Burow(Director)inRichard Heyman(Director)inAmir Nashat(Director)in
Co-investorsEcoR1 CapitalLAVLilly Asia VenturesNew Enterprise Associates (NEA)Vivo CapitalARCH Venture Partners+2 more
BiotechCambridge, US
Rick Lundberg(Executive Officer)George P. Vlasuk(Executive Officer, Director)George Vlasuk(Executive Officer, Director)
BoardJean-Francois Formela(Director)inAlan Crane(Director)Marian Nakada(Director)
Co-investorsBrace PharmaSanofi VenturesAtlas VenturePolaris PartnersSR One Capital Management
NewLimit develops epigenetic reprogramming medicines to extend healthspan and treat age-related diseases at the intersection of computer science and biotechnology.
AI & Machine LearningBiotechLongevitySouth San Francisco, US
Brian Armstrong(Co-founder, Board of Directors)inBlake Byers(Director)inJacob Kimmel(Director)inMichael Polansky(Executive Officer)
BoardZavain Dar(Director)in
Co-investorsS32Valor Equity Partners8VCAbstract VenturesBeyond CapitalDraper Associates+6 more
Reservoir Neuroscience is developing therapeutics aimed at repairing the blood-brain barrier.
BiotechHealthtechSan Francisco, US
Aaron Friedman(Executive Officer)Vladimir Senatorov(Director)
BoardTracy Saxton(Director)James Summers(Director)Brian Slingerland(Director)
Co-investorsDolby Family Ventures
Science Corporation develops brain-computer interface and neural engineering technology to restore vision, cognition, and mobility to patients with debilitating conditions.
AI & Machine LearningBiotechDeep TechDigital HealthMedical DevicesAlameda, US
Max Hodak(Chief Executive Officer)
Co-investorsArtis VenturesAvalanche VCBeyond CapitalConversion CapitalDuke Capital PartnersFifty Years+8 more
Skeletalis is developing OASIS, a targeted small-molecule platform for musculoskeletal and bone health that concentrates therapy at sites of active bone loss while preserving the body's natural bone remodeling.
BiotechDeep TechHealthtech
Unity Biotechnology was a biotechnology company that is no longer operating.
BiotechBrisbane, US
Dan Marquess(Executive Officer)Keith Leonard(Executive Officer, Director)Tamara Tompkins(Executive Officer)Bob Goeltz(Executive Officer)Camille Samuels(Director)Jamie Dananberg(Executive Officer)
Co-investorsARCH Venture PartnersCycad Group LLCEcoR1 CapitalKhosla VenturesVenrock
Until develops reversible cryopreservation systems for human donor organs, translating cryobiology into engineered workflows across perfusion, cryoprotectants, cooling, rewarming, and organ-health assessment.
BiotechDeep TechMedical Devices
Co-investorsLux Capital
Rows marked βSEC filingβ are inferred from directors named on the company's SEC Form D β public regulatory data, not a portfolio list published by the firm.